Theory Department, Laboratory for Cheminformatics, National Institute of Chemistry, Hajdrihova 19, SI-1001 Ljubljana, Slovenia.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, SI-1000 Ljubljana, Slovenia.
J Med Chem. 2022 May 12;65(9):6431-6440. doi: 10.1021/acs.jmedchem.2c00039. Epub 2022 May 3.
The continued emergence of bacterial resistance has created an urgent need for new and effective antibacterial agents. Bacterial type II topoisomerases, such as DNA gyrase and topoisomerase IV (topoIV), are well-validated targets for antibacterial chemotherapy. The novel bacterial topoisomerase inhibitors (NBTIs) represent one of the new promising classes of antibacterial agents. They can inhibit both of these bacterial targets; however, their potencies differ on the targets among species, making topoIV probably a primary target of NBTIs in Gram-negative bacteria. Therefore, it is important to gain an insight into the NBTIs key structural features that govern the topoIV inhibition. However, in Gram-positive bacteria, topoIV is also a significant target for achieving dual-targeting, which in turn contributes to avoiding bacterial resistance caused by single-target mutations. In this perspective, we address the structure-activity relationship guidelines for NBTIs that target the topoIV enzyme in Gram-positive and Gram-negative bacteria.
细菌耐药性的不断出现,使得人们迫切需要新的、有效的抗菌药物。细菌 II 型拓扑异构酶,如 DNA 拓扑异构酶和拓扑异构酶 IV(topoIV),是抗菌化疗的良好验证靶点。新型细菌拓扑异构酶抑制剂(NBTIs)是一类有前途的新型抗菌药物。它们可以同时抑制这两种细菌靶点;然而,它们在不同物种的靶点上的效力不同,这使得 topoIV 可能是革兰氏阴性菌中 NBTIs 的主要靶点。因此,深入了解 NBTIs 控制 topoIV 抑制的关键结构特征非常重要。然而,在革兰氏阳性菌中,topoIV 也是实现双重靶向的重要靶点,这反过来有助于避免由单靶点突变引起的细菌耐药性。在这篇观点文章中,我们讨论了针对革兰氏阳性菌和革兰氏阴性菌 topoIV 酶的 NBTIs 的结构-活性关系指导原则。